Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could benefit from its “neuroscience expertise in movement disorders.”